Make or Break An Analgesic Non-Opioid Trial
Unknowns That Can Make or Break a Non-Opioid Analgesic Clinical Trial New and renewed approaches to improve chances of success in developing non-addictive drugs for chronic pain. March 21,
View More Emraclidine for the treatment of schizophrenia
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the
View More Validation of a suite of ERP and QEEG biomarkers
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.
View More Characterizing human abuse potential (HAP) liability
Characterizing human abuse potential liability can be dependent on many factors, including pharmacology, pharmacokinetics, and the intended population. We can help.
View More Preventing and Treating Bunions and Ingrown Toenails
As a CenExel Center of Excellence, JBR works with patients who are managing challenging conditions, such as bunions. As a medical researcher in pain management, I have worked with
View More
